



HHS Public Access

Author manuscript

J Stem Cell Res Transplant. Author manuscript; available in PMC 2016 April 25.

Published in final edited form as:

J Stem Cell Res Transplant. 2015 ; 2(2): .

Adult Stem Cells and Diabetes Therapy

Handenur Ilgun^{1,2}, Joseph William Kim¹, and LuGuang Luo^{1,*}

¹Department of Internal Medicine, Roger Williams Hospital, Boston University School of Medicine, Providence, RI, USA

²Sifa University School of Medicine, Izmir, Turkey

Abstract

The World Health Organization estimates that diabetes will be the fourth most prevalent disease by 2050. Developing a new therapy for diabetes is a challenge for researchers and clinicians in field. Many medications are being used for treatment of diabetes however with no conclusive and effective results therefore alternative therapies are required. Stem cell therapy is a promising tool for diabetes therapy, and it has involved embryonic stem cells, adult stem cells, and pluripotent stem cells. In this review, we focus on adult stem cells, especial human bone marrow stem cells (BM) for diabetes therapy, its history, and current development. We discuss prospects for future diabetes therapy such as induced pluripotent stem cells which have popularity in stem cell research area.

Keywords

Diabetes; Islet β -cell; Bone marrow; Stem cell therapy; Induced pluripotent stem cells

Introduction

Diabetes Mellitus (DM) is a condition where hyperglycemia is caused by islet β -cell function deficiency (type I) and inadequate insulin secretion and/or the context of insulin resistance (type II) [1]. The prevalence of DM is consistently rising throughout the world [2]. Type 1 DM is caused by an autoimmune response to the β -cells, which physiologically release insulin in the pancreas and has two phases. The first phase is insulinitis, where the islets are destroyed by a mixed population of leukocytes. The second phase is diabetes, when most β -cells have been injured. There is no longer adequate insulin production to control blood glucose levels, resulting in hyperglycemia [3]. Type 2 DM consists of two main problems: the insufficient production of insulin from the pancreas and the resistance of body cells to normal or even high levels of insulin [4].

To restore pancreatic β -cell function, recently developing stem cell research provides a great potential. Stem cells are the cells capable of regeneration through division and differentiation into multi-lineage cells [5]. There are three categories of stem cells:

* **Corresponding author:** LuGuang Luo, Prior Building, Floor 2, Center for Stem Cell Research, Department of Medicine/Research, 825 Chalkstone Avenue, Providence, Rhode Island 02908, USA.

embryonic stem cells, induced pluripotent stem cells (iPSCs) and adult stem cells. Embryonic stem cells are derived from embryos and can differentiate into cells of the three germ layers [6]. iPSCs have the unique abilities of self-renewal and differentiation into many types of cell lineages. These are generated from somatic cells using various transcription factors [7]. Adult stem cells are able to regenerate themselves and differentiate into the major specialized cell types of the tissue or organ. Their primary role in living organism is to maintain and repair local tissue [8]. Hematopoietic adult BM, one type of adult stem cells, has the ability to transdifferentiate into the classical embryonic germ cell layers: ectoderm, mesoderm, and endoderm [9]. Recent studies have used BM and its derived stem cells as a source to repair injuries of the heart [10, 11], neuron [10, 12], and muscle [10, 13].

In previous reports, the potential of differentiation of embryonic stem cells and iPSCs into pancreatic-like cells has been shown *in vitro* [14, 15]. Others have also reported that insulin-producing cells can be generated from pancreatic ductal cells, hepatic oval cells, umbilical cord blood stem cells, and neural progenitor cells [14]. However, BM is transdifferentiated into a variety of lineages because it is a rich source of Mesenchymal Stem Cells (MSCs), and more available than the other type of stem cells [14]. In this short review, we focus on how adult stem cells and bone marrow cells affect beta cell function and their potential role in diabetes therapy.

Islet transplantation

After the discovery of immunosuppressive agents, islet transplantation is considered as a feasible clinical choice and provides a promising cure for type 1 diabetes [16]. The Edmonton protocol is the standard for islet transplantation. This protocol requires at least two donors per transplant [17]. However, the limited source of islets, low islet survival rate, and poor islet function post transplantation are significant obstacles to routine islet cell transplantation [2]. The low survival rate and poor islet function is in part due to the islet isolation process, which destroys the supportive microenvironment [18].

Studies have examined the mechanism by which islets perish and lose function during transplantation. Human islet transplantation has not been used as the standard of care for the treatment of type 1 DM due to the fact that islets die and lose function during the isolation process. More than 60% of the pancreatic islet tissue undergoes apoptosis [19]. The apoptotic pathways in islet cells are stimulated by the changes of the islet microenvironment due to the loss of vasculature and their sensitivity to hypoxic conditions [19].

External vascular support of Endothelial Progenitor Cells (EPCs), which is in islet transplants, is lost during the process of islet isolation [20]. Following *in vitro* culture, loss of vascular support affects their dedifferentiation, apoptosis, and necrosis [20, 21]. Their survival rates are unsatisfactory in islets post-isolation because of vascularization damage throughout the islet isolation process [17].

Two types of apoptosis may occur during islet transplantation. The first type is the pro-apoptotic proteins released from islet cells as a result of DNA damage and mitochondria toxin production. The second type is the response to inflammation caused by pre-

inflammatory cytokines such as IL-1 β , TNF- α , and IFN- γ . Transplanted islets will be damaged and lose viability due to the apoptosis,

There are several studies attempting to develop methods and materials to maintain islet function during isolation. Johansson et al. found that formation of composite EPC-MSc islets can enhance the adherence of the EPCs to the islets and revascularization of the EPCs. Proteases from MSCs contribute to EPC migration [20]. Upregulation of the expression of angiopoietin and Vascular Endothelial Growth Factor (VEGF) in EPCs contribute to an increase in angiogenesis and stabilization of the vasculature. This was performed by MSCs [20, 22].

Effect of BM to islet transplantation

Previous studies show that BM cells have the ability to repair non hematopoietic tissues, including CNS, renal, pulmonary, and skin tissue [17]. BM may even play a role in tissue regeneration in these organs [17]. Luo et al. established that the rate of apoptosis, apoptosis related inflammatory factors, extra cellular ATP accumulation, and ATP receptor P2X7R expression reduced in co-cultured human islets with human BM versus only human islets culture. It is shown that BM co-cultured with human pancreatic islets can inhibit β -cell apoptosis and promote insulin positive cells [19].

BM contains all type of BM subpopulation, including EPCs. BM containing EPCs are capable of revascularization. EPCs from BM can protect islet β -cells from injury caused by hypoxia and apoptosis. BM has an anti-apoptotic effect by decreasing IL-1 β and ATP levels and consequently releases them into the extracellular matrix. Thus, islets are protected from apoptosis by these anti-apoptotic effects and revascularization. This takes place even in long term *in vitro* culture conditions.

A damaged human islet is repaired when human islets are co-cultured with BM [17]. Levels of insulin release are enhanced from islets in long term co-culture with BM. It was demonstrated that the first 6 days of a islet-BM co-culture resulted in a monolayer surrounding the islet structure. Eventually insulin response to glucose was enhanced. This improvement continues to be found in long term culture.

On the other hand, islet-only cultures rapidly lose their morphology within the first week. The islet cells undergo degeneration of their monolayer forms and undergo apoptosis in long term culture. They showed spikes of insulin levels on days 15 and 28 due to leakage of intercellular insulin from dying β -cells. Basal insulin release levels gradually decreased. No viable islet cells were found after 6 months islet only culture [17].

Pancreatic islet β -cell growth is supported by BM *in vivo* which may be manipulated to generate new β -cells *in vitro* [23, 24]. BM cells may repair human islets which are injured from the isolation process. BM has various subpopulations which may play different roles. For instance, BM-derived MSCs possess the ability to differentiate into multiple lineages including adipogenic [10, 25], osteogenic [10] [26], and chondrogenic tissues [10, 27]. Alternatively, BM can develop a biological scaffold microenvironment. Meanwhile EPCs,

which is the other type of BM subpopulation, produces undergo angiogenesis and vascularization [9].

In spite of the evidence for BM subpopulation differentiation into β -cells, mice studies have not been consistent. In a previous study of mice, injection of only EPCs into injured pancreas increased the number of donor and recipient EPCs, but there was no evidence for EPCs differentiation into β -cells [10, 28]. It is not surprising that EPCs can promote revascularization. It enhances the islet microenvironment that was damaged from the islet isolation process. Recent research demonstrated human islet survival and function are improved by allogenic BM for more than six months [17]. It shows that regeneration is achieved by a synergy between angiogenesis and paracrine factor. Luo et al. examined two major subpopulations of BM, MSCs and EPCs, and found that they influence human islet β -cell survival and function [10]. The BM and its derivatives MSCs and EPCs have considerably different impacts on β -cell population under similar culture conditions even if obtained from the same donor. Islet injury is repaired by MSCs and EPCs, but they cannot increase the β -cell population since β -cell related transcription factors are not activated. Nevertheless, the effect of co-cultured BM on human islet β -cell regeneration has not been observed in other BM subpopulations. Only BM has the capability of improving β -cell regeneration [10].

Future of stem cell therapy for diabetes

iPSCs are a novel source of cell therapy for diabetes, as well as other multigenic diseases. iPSCs are reprogrammed from patient cells by transcription factors. For instance, three transcription factors (OCT4, SOX2, and KLF4) regenerate iPSCs from patient fibroblast [29]. These iPSCs begin acting as β -like cells and release insulin. Transplantation of homologous pancreatic islets is problematic due to immune rejection. Therefore, stem cell therapy with autologous iPSCs is a favorable treatment for diabetes [30].

Alipio et al. showed that iPSCs differentiated into β -like cells that were similar to the endogenous insulin-secreting cells in mice. iPSCs can differentiate into insulin-secreting cells *in vitro* [4]. *In vivo*, iPSCs reduce high glucose level in the diabetic mouse model [4].

An alternative cell source is human umbilical cord-derived mesenchymal stem cells (UCMSCs). UCMSCs can be easily isolated from the umbilical cord [31]. They have considerably more pluripotency than adult stem cells. They express the pluripotency markers OCT4, SOX2, and c-MYC. In contrast to embryonic stem cells, transplanted USMSCs are not associated with tumors. Also they are inherently immune-suppressive and available for use as a cell source with few ethical disputes. Therefore, USMSCs harbor a great potential for diabetes treatment [32].

Conclusion

Adult stem cells derived from BM are potential cells for diabetes therapy. BM can suppress inflammation and inhibit apoptosis in transplanted islets. It initiates revascularization and differentiation to β -cells in diabetic pancreases. Transplantation of allogenic BM does not cause immune rejection in recipient. Thus, BM derived stem cell therapy is a promising

therapeutic strategy for treatment of diabetes. Other types of stem cells like iPSCs and USMSCs are also being developed for diabetes treatment.

Acknowledgments

This work was funded by grants from the US National Institutes of Health (NIH) 1R01DK097380-01A1 (L.L.) and National Center for Research Resources (COBRE, 5P20RR018757-10), Juvenile Diabetes Research Foundation International (JDRF) foundation 1-2007-180 (L.L.) and Roger Williams Hospital Research fund (L.L.).

References

1. Wang Z, Xiong F, Hassani M, Luo JZ, Luo LG. Bone marrow increases human islets insulin positive cells in co-culture: quantification with flow cytometry. *J Diabetes*. 2011; 4:109–117.
2. Luo LG. Islet transplantation challenge-Human islet longevity: A potential solution from bone marrow cells. *J Bioanal Biomed*. 2012; 4:4.
3. Mathis D, Vence L, Benoist C. beta Cell death during progression to diabetes. *Nature*. 2001; 414:792–798. [PubMed: 11742411]
4. Alipio Z, Liao W, Roemer EJ, Waner M, Fink LM, Ward DC, Ma Y. Reversal of hyperglycemia in diabetic mouse models using induced-pluripotent stem (iPS)-derived pancreatic beta-like cells. *Proc Natl Acad Sci U S A*. 2010; 107:13426–13431. [PubMed: 20616080]
5. Ullah I, Subbarao RB, Rho GJ. Human mesenchymal stem cells - current trends and future prospective. *Biosci Rep*. 2015:35.
6. What are embryonic stem cells? In *Stem Cell Information*. National Institutes of Health, U.S. Department of Health and Human Services; [Online]
7. Singh VK, Kalsan M, Kumar N, Saini A, Chandra R. Induced pluripotent stem cells: applications in regenerative medicine, disease modeling, and drug discovery. *Front Cell Dev Biol*. 2015; 3:2. [PubMed: 25699255]
8. What are adult stem cells? In *Stem Cell Information*. National Institutes of Health, U.S. Department of Health and Human Services; [Online]
9. Hovs J. Adult stem cell therapy beyond haemopoietic stem cell transplantation? An update. *Transpl Immunol*. 2005; 14:221–223. [PubMed: 15982566]
10. Luo L, Xiong F, Ravassard P, Luo JZ. Human bone marrow subpopulations sustain human islet function and viability *in vitro*. *Br J Med Med Res*. 2015; 8:576–587.
11. Kuethe F, Richartz BM, Kasper C, Sayer HG, Hoeffken K, Werner GS, et al. Autologous intracoronary mononuclear bone marrow cell transplantation in chronic ischemic cardiomyopathy in humans. *Int J Cardiol*. 2005; 100:485–491. [PubMed: 15837094]
12. Dezawa M, Hoshino M, Nabeshima Y, Ide C. Marrow stromal cells: implications in health and disease in the nervous system. *Curr Mol Med*. 2005; 5:723–732. [PubMed: 16305495]
13. Abedi M, Greer DA, Colvin GA, Demers DA, Dooner MS, Harpel JA, et al. Robust conversion of marrow cells to skeletal muscle with formation of marrow-derived muscle cell colonies: a multifactorial process. *Exp Hematol*. 2004; 32:426–434. [PubMed: 15145210]
14. Pokrywczynska M, Lewandowska MA, Krzyzanowska S, Jundzill A, Rasmus M, Warda K. Transdifferentiation of Bone Marrow Mesenchymal Stem Cells into the Islet-Like Cells: the Role of Extracellular Matrix Proteins. *Arch Immunol Ther Exp (Warsz)*. 2015; 63:377–384. [PubMed: 25957583]
15. Tateishi K, He J, Taranova O, Liang G, D'Alessio AC, Zhang Y. Generation of insulin-secreting islet-like clusters from human skin fibroblasts. *J Biol Chem*. 2008; 283:31601–31607. [PubMed: 18782754]
16. Luo JZ, Xiong F, Al-Homsi AS, Ricordi C, Luo L. Allogeneic bone marrow cocultured with human islets significantly improves islet survival and function *in vivo*. *Transplantation*. 2013; 95:801–809. [PubMed: 23416682]
17. Luo L, Badiavas E, Luo JZ, Maizel A. Allogeneic bone marrow supports human islet beta cell survival and function over six months. *Biochem Biophys Res Commun*. 2007; 361:859–864. [PubMed: 17686461]

18. Luo JZ, Xiong F, Al-Homsi AS, Roy T, Luo LG. Human BM stem cells initiate angiogenesis in human islets *in vitro*. *Bone Marrow Transplant*. 2011; 46:1128–1137. [PubMed: 21132023]
19. Luo LG, Luo JZ. Anti-apoptotic Effects of Bone Marrow on Human Islets: A Preliminary Report. *J Stem Cell Res Ther*. 2015;5.
20. Johansson U, Rasmusson I, Niclou SP, Forslund N, Gustavsson L, Nilsson B, Korsgren O. Formation of composite endothelial cell-mesenchymal stem cell islets: a novel approach to promote islet revascularization. *Diabetes*. 2008; 57:2393–2401. [PubMed: 18519803]
21. Giuliani M, Moritz W, Bodmer E, Dindo D, Kugelmeier P, Lehmann R, Gassmann M. Central necrosis in isolated hypoxic human pancreatic islets: evidence for postisolation ischemia. *Cell Transplant*. 2005; 14:67–76. [PubMed: 15789664]
22. Zacharek A, Chen J, Cui X, Li A, Li Y, Roberts C, et al. Angiopoietin1/Tie2 and VEGF/Flk1 induced by MSC treatment amplifies angiogenesis and vascular stabilization after stroke. *J Cereb Blood Flow Metab*. 2007; 27:1684–1691. [PubMed: 17356562]
23. Luo LG, Xiong F, Ravassard P, Luo JZ. Human bone marrow subpopulations sustain human islet function and viability *in vitro*. *Br J Med Med Res*. 2015; 8:576–587.
24. Gangaram-Panday ST, Faas MM, de Vos P. Towards stem-cell therapy in the endocrine pancreas. *Trends Mol Med*. 2007; 13:164–173. [PubMed: 17307397]
25. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, et al. Multilineage potential of adult human mesenchymal stem cells. *Science*. 1999; 284:143–147. [PubMed: 10102814]
26. Lennon DP, Haynesworth SE, Arm DM, Baber MA, Caplan AI. Dilution of human mesenchymal stem cells with dermal fibroblasts and the effects on *in vitro* and *in vivo* osteochondrogenesis. *Dev Dyn*. 2000; 219:50–62. [PubMed: 10974671]
27. Li M, Takenaka H, Asai J, Ibusuki K, Mizukami Y, Maruyama K, et al. Endothelial progenitor thrombospondin-1 mediates diabetes-induced delay in reendothelialization following arterial injury. *Circ Res*. 2006; 98:697–704. [PubMed: 16484619]
28. Mathews V, Hanson PT, Ford E, Fujita J, Polonsky KS, Graubert TA. Recruitment of bone marrow-derived endothelial cells to sites of pancreatic beta-cell injury. *Diabetes*. 2004; 53:91–98. [PubMed: 14693702]
29. Maehr R, Chen S, Snitow M, Ludwig T, Yagasaki L, Goland R, Leibel RL. Generation of pluripotent stem cells from patients with type 1 diabetes. *Proc Natl Acad Sci U S A*. 2009; 106:15768–15773. [PubMed: 19720998]
30. Raikwar SP, Kim EM, Sivitz WI, Allamargot C, Thedens DR, Zavazava N. Human iPS cell-derived insulin producing cells form vascularized organoids under the kidney capsules of diabetic mice. *PLoS One*. 2015; 10:e0116582. [PubMed: 25629318]
31. Tsai PJ, Wang HS, Shyr YM, Weng ZC, Tai LC, Shyu JF, Chen TH. Transplantation of insulin-producing cells from umbilical cord mesenchymal stem cells for the treatment of streptozotocin-induced diabetic rats. *J Biomed Sci*. 2012; 19:47. [PubMed: 22545626]
32. Guan LX, Guan H, Li HB, Ren CA, Liu L, Chu JJ, Dai LJ. Therapeutic efficacy of umbilical cord-derived mesenchymal stem cells in patients with type 2 diabetes. *Exp Ther Med*. 2015; 9:1623–1630. [PubMed: 26136869]